Published in Curr Drug Targets on May 01, 2011
The blood-testis barrier and its implications for male contraception. Pharmacol Rev (2011) 2.10
Epigenetic resensitization to platinum in ovarian cancer. Cancer Res (2012) 1.88
Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res (2012) 1.49
Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain. Proc Natl Acad Sci U S A (2013) 1.30
Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway. PLoS One (2012) 1.20
Drug transporters, the blood-testis barrier, and spermatogenesis. J Endocrinol (2010) 1.05
Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer. BMC Genomics (2013) 0.93
2,4-D resistance in wild radish: reduced herbicide translocation via inhibition of cellular transport. J Exp Bot (2016) 0.90
Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model. Clin Cancer Res (2015) 0.87
P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Invest New Drugs (2015) 0.85
Neoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancer. PLoS One (2013) 0.85
Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925. Br J Cancer (2014) 0.84
ABC transporter activity linked to radiation resistance and molecular subtype in pediatric medulloblastoma. Exp Hematol Oncol (2013) 0.84
Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer. BMC Cancer (2013) 0.83
Design and synthesis of human ABCB1 (P-glycoprotein) inhibitors by peptide coupling of diverse chemical scaffolds on carboxyl and amino termini of (S)-valine-derived thiazole amino acid. J Med Chem (2014) 0.80
Reversal of multidrug resistance by the anti-malaria drug artesunate in the esophageal cancer Eca109/ABCG2 cell line. Oncol Lett (2013) 0.79
Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro. PLoS One (2013) 0.78
The anthelmintic triclabendazole and its metabolites inhibit the membrane transporter ABCG2/BCRP. Antimicrob Agents Chemother (2012) 0.78
Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1. Biochem Pharmacol (2013) 0.78
Drug transporter-independent liver cancer cell killing by a marine steroid methyl spongoate via apoptosis induction. J Biol Chem (2011) 0.78
Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Sci Rep (2014) 0.78
Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance. Oncotarget (2016) 0.78
A 20(S)-protopanoxadiol derivative overcomes multi-drug resistance by antagonizing ATP-binding cassette subfamily B member 1 transporter function. Oncotarget (2016) 0.77
Redox Control of Multidrug Resistance and Its Possible Modulation by Antioxidants. Oxid Med Cell Longev (2016) 0.77
bba, a synthetic derivative of 23-hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10). PLoS One (2013) 0.77
Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1). PLoS One (2013) 0.76
The ABCs of Candida albicans Multidrug Transporter Cdr1. Eukaryot Cell (2015) 0.76
Screening dietary flavonoids for the reversal of P-glycoprotein-mediated multidrug resistance in cancer. Mol Biosyst (2016) 0.75
Using the BacMam Baculovirus System to Study Expression and Function of Recombinant Efflux Drug Transporters in Polarized Epithelial Cell Monolayers. Drug Metab Dispos (2015) 0.75
Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1. Sci Rep (2017) 0.75
β-casein nanovehicles for oral delivery of chemotherapeutic Drug combinations overcoming P-glycoprotein-mediated multidrug resistance in human gastric cancer cells. Oncotarget (2016) 0.75
Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats. Sci Rep (2016) 0.75
Strategies to target drugs to gliomas and CNS metastases of solid tumors. J Neurol (2015) 0.75
The Efflux Transporter ABCG2 Maintains Prostate Stem Cells. Mol Cancer Res (2016) 0.75
Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1. Sci Rep (2016) 0.75
Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis. PLoS One (2016) 0.75
Anti-Cancer Phytometabolites Targeting Cancer Stem Cells. Curr Genomics (2017) 0.75
2-Trifluoromethyl-2-Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)-Mediated Multidrug Resistance: Synthesis and Biological Evaluations. J Cell Biochem (2017) 0.75
Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines. Cancer Lett (2017) 0.75
Downregulation of ABC Transporters in Non-neoplastic Tissues Confers Better Prognosis for Pancreatic and Colorectal Cancer Patients. J Cancer (2017) 0.75
Targeting P-glycoprotein: Investigation of piperine analogs for overcoming drug resistance in cancer. Sci Rep (2017) 0.75
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2006) 15.18
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2003) 12.24
Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (1992) 8.84
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta (1976) 7.41
Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol (1999) 6.62
A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A (1998) 6.47
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell (1994) 6.02
Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res (1981) 4.30
The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood (2002) 4.02
A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst (2000) 3.98
P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest (1996) 3.75
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev (2003) 3.69
Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci (2005) 3.19
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A (1997) 2.91
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol (2002) 2.90
Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet (2005) 2.80
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res (1999) 2.70
Overview: ABC transporters and human disease. J Bioenerg Biomembr (2001) 2.60
A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res (1998) 2.58
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest (1999) 2.57
P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med (1991) 2.32
Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res (2000) 2.32
ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev (2007) 2.31
The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett (2005) 2.25
In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res (1993) 2.15
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther (2007) 2.11
Novel agents on the horizon for cancer therapy. CA Cancer J Clin (2009) 2.11
Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem (1987) 1.99
ABCG2: a perspective. Adv Drug Deliv Rev (2008) 1.97
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res (2001) 1.95
ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev (2009) 1.92
Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest (2002) 1.90
Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia (2007) 1.89
The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol (1999) 1.84
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta (2009) 1.79
P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res (2007) 1.74
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol (2001) 1.70
The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun (1995) 1.68
Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta (1999) 1.62
Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther (2000) 1.61
Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma (2007) 1.58
P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther (2009) 1.56
ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther (2006) 1.49
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res (2002) 1.48
Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest (1997) 1.48
Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res (2009) 1.42
Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest (1986) 1.42
Inventory and function of yeast ABC proteins: about sex, stress, pleiotropic drug and heavy metal resistance. Biochim Biophys Acta (1999) 1.42
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res (2004) 1.41
Quinidine-digoxin interaction: Pharmacokinetics, underlying mechanism and clinical implications. N Engl J Med (1979) 1.41
Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res (1996) 1.39
Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett (1999) 1.38
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2009) 1.38
Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest (1996) 1.37
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther (2008) 1.36
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res (2004) 1.35
Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res (2004) 1.35
Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A (1992) 1.34
Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol (2004) 1.33
Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin Cancer Res (2003) 1.32
Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol (2008) 1.32
Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res (1994) 1.27
Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol (1998) 1.26
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res (2007) 1.24
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res (2006) 1.23
Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev (2008) 1.21
Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res (2002) 1.21
Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol (2006) 1.20
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol (2007) 1.19
Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol (1989) 1.16
Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur J Cancer (1991) 1.15
A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res (2009) 1.15
Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther (2005) 1.15
Phase I study of vinblastine and verapamil given by concurrent iv infusion. Cancer Treat Rep (1985) 1.15
VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res (2004) 1.13
Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs (1997) 1.13
The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr (2001) 1.13
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res (1999) 1.12
P-glycoprotein: so many ways to turn it on. J Clin Pharmacol (2007) 1.11
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther (2002) 1.11
Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J Neurochem (2007) 1.08
Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol (2010) 1.07
Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A (2000) 1.07
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer (1997) 1.06
The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer (1997) 1.05
Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res (2008) 1.03
Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther (2004) 1.03
Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res (2003) 1.01
Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. J Clin Oncol (2006) 1.01
Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res (2007) 1.01
Genomics and the mechanism of P-glycoprotein (ABCB1). J Bioenerg Biomembr (2007) 1.00
A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol (2002) 0.99
Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res (1998) 0.99
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer (2001) 0.99
Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol (2009) 0.98
Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem Pharmacol (1996) 0.98
Reconstitution of functional water channels in liposomes containing purified red cell CHIP28 protein. Biochemistry (1992) 3.84
HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry (1998) 2.87
Overview: ABC transporters and human disease. J Bioenerg Biomembr (2001) 2.60
P-glycoprotein and multidrug resistance. Curr Opin Genet Dev (1996) 2.33
Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A (1997) 2.10
Isoprenyl diphosphate synthases. Biochim Biophys Acta (2000) 2.04
Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry (1998) 1.75
Reconstitution of sugar phosphate transport systems of Escherichia coli. J Biol Chem (1986) 1.69
Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proc Natl Acad Sci U S A (2000) 1.58
Identification, purification, and reconstitution of OxlT, the oxalate: formate antiport protein of Oxalobacter formigenes. J Biol Chem (1992) 1.56
Bacterial anion exchange. Use of osmolytes during solubilization and reconstitution of phosphate-linked antiport from Streptococcus lactis. J Biol Chem (1986) 1.55
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia (2007) 1.52
Anion-exchange mechanisms in bacteria. Microbiol Rev (1990) 1.47
Calcium efflux from Escherichia coli. Evidence for two systems. J Biol Chem (1984) 1.47
Reconstitution of a bacterial periplasmic permease in proteoliposomes and demonstration of ATP hydrolysis concomitant with transport. Proc Natl Acad Sci U S A (1989) 1.46
Ultrastructure, pharmacologic inhibition, and transport selectivity of aquaporin channel-forming integral protein in proteoliposomes. Biochemistry (1994) 1.44
Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem (1996) 1.43
Chain-length determination mechanism of isoprenyl diphosphate synthases and implications for molecular evolution. Trends Biochem Sci (1999) 1.30
Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem Pharmacol (2004) 1.29
The neuronal architecture of Xenopus retinal ganglion cells is sculpted by rho-family GTPases in vivo. J Neurosci (1999) 1.29
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br J Cancer (2008) 1.27
Variable stoichiometry of phosphate-linked anion exchange in Streptococcus lactis: implications for the mechanism of sugar phosphate transport by bacteria. Proc Natl Acad Sci U S A (1986) 1.22
Phosphate/hexose 6-phosphate antiport in Streptococcus lactis. J Bacteriol (1984) 1.21
Characterization of phosphate:hexose 6-phosphate antiport in membrane vesicles of Streptococcus lactis. J Biol Chem (1984) 1.17
Cell surface Lactobacillus plantarum LA 318 glyceraldehyde-3-phosphate dehydrogenase (GAPDH) adheres to human colonic mucin. J Appl Microbiol (2008) 1.15
Correlation between steady-state ATP hydrolysis and vanadate-induced ADP trapping in Human P-glycoprotein. Evidence for ADP release as the rate-limiting step in the catalytic cycle and its modulation by substrates. J Biol Chem (2000) 1.14
Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. J Biol Chem (2001) 1.13
The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr (2001) 1.13
Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia (2007) 1.12
Cloning of a gene from Escherichia coli that confers resistance to fosmidomycin as a consequence of amplification. Gene (1996) 1.11
Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system. Mol Biol Cell (1996) 1.11
Cauda equina syndrome complicating pneumococcal meningitis. Pediatr Neurol (1999) 1.10
The mechanism of glucose 6-phosphate transport by Escherichia coli. J Biol Chem (1988) 1.09
Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system. J Membr Biol (2000) 1.09
Reconstitution of ATP-dependent calcium transport from streptococci. J Biol Chem (1986) 1.08
Photoaffinity labeling of human P-glycoprotein: effect of modulator interaction and ATP hydrolysis on substrate binding. Methods Enzymol (1998) 1.04
Heterologous expression systems for P-glycoprotein: E. coli, yeast, and baculovirus. J Bioenerg Biomembr (1995) 1.04
Mechanism of action of human P-glycoprotein ATPase activity. Photochemical cleavage during a catalytic transition state using orthovanadate reveals cross-talk between the two ATP sites. J Biol Chem (1998) 1.02
Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport. Biochemistry (1998) 1.01
Involvement of cell-mediated killing in apoptosis in histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto disease). Histopathology (1996) 0.95
Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein. Biochemistry (1998) 0.95
Reconstitution of the lysosomal proton pump. Proc Natl Acad Sci U S A (1987) 0.95
Functional reconstitution of prokaryote and eukaryote membrane proteins. Arch Biochem Biophys (1989) 0.93
Protein design of geranyl diphosphate synthase. Structural features that define the product specificities of prenyltransferases. J Biochem (1999) 0.87
The necessity for dual food intake to provoke food-dependent exercise-induced anaphylaxis (FEIAn): a case report of FEIAn with simultaneous intake of wheat and umeboshi. J Allergy Clin Immunol (2001) 0.86
Effects of phosphorylation of P-glycoprotein on multidrug resistance. J Bioenerg Biomembr (1995) 0.86
Overexpression of an archaeal geranylgeranyl diphosphate synthase in Escherichia coli cells. Biosci Biotechnol Biochem (1998) 0.84
Functionally similar vanadate-induced 8-azidoadenosine 5'-[alpha-(32)P]Diphosphate-trapped transition state intermediates of human P-glycoprotin are generated in the absence and presence of ATP hydrolysis. J Biol Chem (2001) 0.84
Use of cultured tubular cells isolated from human urine for investigation of renal transporter. Clin Nephrol (2000) 0.83
Synthesis and preliminary analysis of a P-glycoprotein-specific [3H]-benzophenone photoaffinity label based on (-)-stipiamide. Bioorg Med Chem Lett (2000) 0.83
Calcium, sodium, phosphate and arsenate transport in cells and vesicles of Escherichia coli. Prog Clin Biol Res (1984) 0.81
Anion exchange in bacteria: reconstitution of phosphate: hexose 6-phosphate antiport from Streptococcus lactis. Methods Enzymol (1986) 0.81
New screening methods for probiotics with adhesion properties to sialic acid and sulphate residues in human colonic mucin using the Biacore assay. J Appl Microbiol (2013) 0.81
Mechanism of product chain length determination for heptaprenyl diphosphate synthase from Bacillus stearothermophilus. Eur J Biochem (2000) 0.81
Identification of genes affecting lycopene formation in Escherichia coli transformed with carotenoid biosynthetic genes: candidates for early genes in isoprenoid biosynthesis. J Biochem (1998) 0.81
Ion extrusion systems in bacteria. Ann N Y Acad Sci (1985) 0.79
Bacterial expression of the linker region of human MDR1 P-glycoprotein and mutational analysis of phosphorylation sites. Biochemistry (1995) 0.79
Evidence for the vectorial nature of drug (substrate)-stimulated ATP hydrolysis by human P-glycoprotein. J Biol Chem (2001) 0.78
Anion exchange in bacteria. Variable stoichiometry of phosphate: sugar 6-phosphate antiport. Ann N Y Acad Sci (1985) 0.78
High sialic acid reactivity of sugar chain structure Lewis-X in patients with mental retardation. Biol Psychiatry (1997) 0.78
A glycoside of Nicotina tabacum affects mouse dopaminergic behavior. Methods Find Exp Clin Pharmacol (2003) 0.77
The synthesis and evaluation of a solution phase indexed combinatorial library of non-natural polyenes for reversal of P-glycoprotein mediated multidrug resistance. J Org Chem (2000) 0.77
Exploiting multidrug resistance to treat cancer. Cold Spring Harb Symp Quant Biol (1994) 0.77
Relationship between antidepressants and glycolipids in the forced swimming test in mice. Methods Find Exp Clin Pharmacol (2000) 0.76
Portal and mesenteric vein and inferior vena cava thrombosis associated with antiphospholipid syndrome. Intern Med (2001) 0.75
Alpha 2-adrenoceptor activity induces the antidepressant-like glycolipid in mouse forced swimming. Methods Find Exp Clin Pharmacol (2001) 0.75
Reconstitution of a passive Ca(2+)-transport pathway from the basolateral plasma membrane of rat parotid gland acinar cells. J Membr Biol (1995) 0.75
[Statistical studies of student clinical practice. 1. Clinical practice of operative dentistry from 1983 to 1989]. Higashi Nihon Shigaku Zasshi (1990) 0.75
[Effects of chronic ethanol intake on sugar chain structures of IgG in mice]. Arukoru Kenkyuto Yakubutsu Ison (1995) 0.75
Measurement of radon concentration in water using the portable radon survey meter. Radiat Prot Dosimetry (2011) 0.75
Glycoside in schizophrenic patients sera affects behavior of mouse forced swimming. Tohoku J Exp Med (2001) 0.75
[A case of acute pulmonary embolism associated with squatting]. Nihon Kokyuki Gakkai Zasshi (2001) 0.75
Phospholipid metabolism in E. coli during growth in high glucose medium. Indian J Biochem Biophys (1980) 0.75
Reconstitution of phosphate-linked antiport from Streptococcus lactis. Biochem Biophys Res Commun (1985) 0.75
[A case of advanced gastric cancer treated with neoadjuvant chemotherapy of low-dose CPT-11 + CDDP]. Gan To Kagaku Ryoho (2001) 0.75
[A study for non-asbestos casting liners. An experimental study of the adaptability of MOD casting to die]. Higashi Nihon Shigaku Zasshi (1990) 0.75
Behavioral effect of herbal glycoside in the forced swimming test. Methods Find Exp Clin Pharmacol (2002) 0.75
[The roles of various media in the decision making processes for recycling behavior: a path analysis model]. Shinrigaku Kenkyu (1997) 0.75
[A case of neonatal herpes infection which proved to be a mixed infection of herpes simplex virus type 1 and type 2]. Kansenshogaku Zasshi (1996) 0.75